Early Breast Cancer Coverage Brought to You By

ESMO 2025 - Early Breast Cancer

5-Year Results From NATALEE Demonstrate Sustained Effect: Evaluating Ribociclib + NSAIs in HR-Positive/HER2-Negative Early Breast Cancer
ESMO 2025 - Early Breast Cancer
The 5-year landmark analysis of the NATALEE trial highlights sustained improvements with adjuvant ribociclib combined with nonsteroidal aromatase inhibitors (NSAIs) for hormone receptor (HR)-positive/HER2-negative early breast cancer. Read More ›

Page 3 of 3


© Amplity, Inc. All Rights Reserved. Privacy Policy